The aging body actively reshapes itself in ways that help tumors propagate.
For decades, clinicians have observed that breast cancer claims older lives with particular ferocity, yet the biological reason remained elusive. Researchers at Georgetown University's Lombardi Comprehensive Cancer Center have now identified a protein called RAGE as a central architect of this disparity — a molecular receptor that grows more active with age, stoking chronic inflammation and quietly preparing the body to receive and sustain metastatic disease. The discovery reframes a long-standing question: it is not only the tumor that determines fate, but the aging landscape in which it grows.
- Older breast cancer patients die at higher rates than younger ones even when their primary tumors appear equally aggressive — a gap that has haunted oncology for decades without a clear molecular explanation.
- A pandemic-era accident in the lab — mice that aged longer than intended — gave researchers an unexpected window into how dramatically the older body accelerates cancer spread, with far more lung metastases appearing in aged animals despite similar tumor growth.
- The RAGE protein emerges as the key culprit: as the body ages, inflammatory molecules accumulate and activate RAGE, effectively laying out a biological welcome mat that makes invasion and metastasis easier for cancer cells.
- Analysis of over a thousand patient records confirmed the laboratory findings — higher RAGE-related gene expression consistently correlated with worse clinical outcomes, bridging the gap between mouse models and human disease.
- A drug already in existence, TTP488, has shown it can suppress this pathway in preclinical models, and a clinical trial is now underway, marking a concrete step toward therapies designed for the aging body rather than the tumor alone.
Breast cancer has long been known to behave more lethally in older patients, but the biological mechanism behind that disparity has resisted explanation. A research team at Georgetown's Lombardi Comprehensive Cancer Center now points to a protein called RAGE — a cell-surface receptor that grows increasingly active with age and amplifies the body's inflammatory signals in ways that help tumors spread.
The insight emerged from an unlikely source. When the COVID-19 pandemic slowed laboratory activity, research mice aged beyond their intended window. Rather than a setback, this became an opportunity: scientists could now compare tumor behavior in young and old animals side by side. Across three models of triple-negative breast cancer, older mice developed dramatically more lung metastases than younger ones, even when primary tumors grew at similar rates. When the RAGE gene was removed entirely, that age-related surge in metastasis nearly disappeared.
The mechanism runs through inflammation. With age, two proteins — S100 and HMGB1 — accumulate in tumors and at metastatic sites, activating RAGE and making the tissue environment more hospitable to invading cancer cells. The aging body, in this view, does not merely become more vulnerable to cancer; it actively remodels itself in ways that help cancer propagate.
To test whether this translated to human patients, the team examined records from more than a thousand women. Higher expression of AGER, the gene encoding RAGE, along with related inflammatory signatures, correlated strongly with worse outcomes — a clinical confirmation of what the lab had shown.
A drug called TTP488, already under investigation for other age-related conditions, has demonstrated the ability to reduce tumor cell invasiveness in preclinical models. Georgetown is now running a clinical trial evaluating its safety in breast cancer patients undergoing chemotherapy. The broader implication is significant: cancer research has long focused on mutations within tumor cells as the primary driver of disease, but this work insists that the host environment — the aging immune system, the accumulated inflammation, the transformed biological landscape of an older body — is equally decisive.
Breast cancer behaves differently in older bodies. The tumors spread faster, the outcomes are grimmer, and for decades researchers have struggled to explain why. A team at Georgetown's Lombardi Comprehensive Cancer Center may have found a crucial piece of the answer: a protein called RAGE that sits on cell surfaces and, as we age, becomes increasingly active at amplifying inflammatory signals throughout the body.
The discovery emerged partly by accident. During the COVID-19 pandemic, when lab activity slowed, some of the research colony's mice aged longer than planned. What might have been a setback became an unexpected gift. The scientists could now compare tumor behavior directly between young and old animals—a comparison that is normally difficult and expensive to conduct. Using three different models of triple-negative breast cancer, one of the most aggressive forms of the disease, they found that older mice developed far more lung metastases than younger ones, even when their primary tumors grew at similar rates. When the researchers genetically removed the RAGE gene entirely, that age-related surge in metastasis nearly vanished.
The mechanism appears to work through inflammation. As the body ages, levels of inflammatory molecules that activate RAGE climb steadily. Two proteins in particular—S100 and HMGB1—accumulate in both primary tumors and in metastatic sites. These molecules act like a welcome mat for cancer cells, making invasion and spread easier. Barry Hudson, the study's lead author and an associate professor at Lombardi, describes RAGE as a key mediator of these harmful age-related pathways. The aging body, in other words, doesn't just become more vulnerable to cancer—it actively reshapes itself in ways that help tumors propagate.
To test whether these findings held in human patients, the team analyzed breast cancer data from more than a thousand women. Higher expression of AGER, the gene that codes for RAGE, along with related inflammatory genetic signatures, correlated strongly with worse outcomes. The laboratory observations had a clinical echo.
RAGE is already being investigated as a therapeutic target in various age-related diseases, which suggested a possible path forward. In earlier work, Hudson's group showed that a RAGE inhibitor called TTP488, also known as azeliragon, could suppress breast cancer metastasis in preclinical models. When they tested it in the lab using serum from aged mice, TTP488 reduced the invasiveness of tumor cells. The drug has shown a favorable safety profile in humans, making it a reasonable candidate for further study.
Georgetown is currently running a clinical trial to evaluate TTP488 in breast cancer patients undergoing chemotherapy, with a focus on safety and cognitive outcomes. The trial represents a shift in how researchers think about cancer in aging bodies. For years, the field has centered on mutations within tumor cells themselves as the primary driver of disease. But Hudson's work underscores something equally important: the host environment—the aging immune system, the chronic inflammation, the systemic changes that accumulate over decades—shapes how aggressively cancer behaves. An older body is not simply a younger body that has grown old. It is a fundamentally different landscape, one that cancer has learned to navigate with devastating efficiency.
Notable Quotes
Aging not only increases cancer risk, but actively modifies the body in ways that favor tumor spread. RAGE appears to be a key mediator of these harmful age-related pathways.— Barry Hudson, associate professor, Georgetown Lombardi Comprehensive Cancer Center
While cancer is often thought to originate primarily from mutations within tumor cells, systemic factors like aging and inflammation play a fundamental role in shaping how cancer behaves.— Barry Hudson
The Hearth Conversation Another angle on the story
Why does breast cancer become more lethal specifically as we age? Is it just that older people have weaker immune systems?
It's more active than that. The body doesn't just become passive. Aging actually amplifies inflammatory signals—molecules that cancer cells can exploit. RAGE is the receptor that turns up the volume on those signals.
So the cancer isn't necessarily more aggressive in the tumor itself?
Exactly. The primary tumors grew at similar rates in young and old mice. But the old mice developed far more metastases. The difference isn't in the cancer cell—it's in the soil where the cancer grows.
How did they even discover this? It seems like a hard thing to study.
Partly luck. The pandemic shut down the lab, and some mice just aged longer than expected. Instead of wasting that, they used it. They could finally compare young and old animals directly, which is normally too expensive and difficult to do.
And they found that removing the RAGE gene stopped the metastasis?
Nearly eliminated it. That's the smoking gun. It showed RAGE wasn't just present—it was necessary for the age-related spread.
Is there a drug that blocks RAGE?
Yes, TTP488. It's already being tested in humans for safety. Early results are promising. They're running a trial right now with breast cancer patients on chemotherapy.
What does this mean for older women with breast cancer?
It means the problem isn't inevitable. If you can quiet RAGE, you might be able to slow the spread. It's not a cure, but it's a mechanism we can actually target.